Director/PDMR Shareholding

Summary by AI BETAClose X

Venture Life Group PLC announced that Chief Executive Officer Jerry Randall sold 387,705 ordinary shares at a volume-weighted average price of 66.22 pence per share, totaling approximately £256,600. This sale was to cover the exercise price of options and resulting tax liabilities, following his exercise of options for 483,333 shares. After this transaction, Mr. Randall beneficially holds 2,348,828 ordinary shares, representing 1.82% of the company's issued share capital.

Disclaimer*

Venture Life Group PLC
09 January 2026
 

9 January 2026

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Director/PDMR Shareholding

Further to the announcement on 2 January 2026 of the exercise of options over 483,333 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") by Jerry Randall (Chief Executive Officer), the Company has been notified that, in order to satisfy the payment of the exercise price of the options and the personal tax liabilities resulting from the exercise of the options, Jerry Randall has sold 387,705 Ordinary Shares at a volume-weighted average price of 66.22 pence per Ordinary Share ("the "Share Sale").

Following the Share Sale, Jerry Randall beneficially holds 2,348,828 Ordinary Shares representing approximately 1.82 per cent. of the Company's issued share capital.

 

For further information, please contact:

Venture Life Group PLC                                                                                                    +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer 

Cavendish Capital Markets Limited (Nomad and Broker)                                             +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Jerry Randall

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Sale of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

66.50 pence

66.50 pence

66.90 pence

66.00 pence

66.00 pence

 

100,000

54,690

10,000

50,000

173,015

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

-       387,705 Ordinary Shares

-       66.22 pence

 

 

 

 

 

 

e)

 

Date of the transaction

 

7 / 8 / 9 January 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings